Plain-English translation of NCT06141460 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing , a new gene therapy treatment for wet age-related macular degeneration—a serious eye disease that affects your central vision. The treatment is delivered as a single injection directly into the eye. Researchers want to find the safest and most effective dose of this medication and understand how well it works for people whose eyes have responded to earlier anti-VEGF treatments.
Wet macular degeneration can cause severe vision loss and currently requires repeated eye injections over time. This trial explores whether a one-time gene therapy injection could offer a longer-lasting treatment option for people who have already benefited from anti-VEGF therapy.
You likely qualify if…
You likely don't qualify if…
You would receive a single injection of the medication directly into the space beneath the retina in your eye—performed in an operating room setting. After the injection, you would return for follow-up visits where researchers check your vision, eye health, and any side effects. The study involves two stages: first, researchers test different doses in small groups to find the safest level, then test that dose in a larger group. Visits will include eye exams, imaging scans, and vision tests to monitor how the treatment is working.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
China